The survival rate of patients with pancreatic cancer with KRAS mutation is worse than that of patients with pancreatic cancer with wild-type KRAS, and is reported to be worse in cases with the G12D mutation than in those with the G12V mutation. This evidence concerns the gene KRAS and pancreatic neoplasm.